Form 4: Arvinas Inc. Executive Noah Berkowitz Reports Stock and Option Grants

Chief Medical Officer Noah Berkowitz of Arvinas Inc. reports the acquisition of restricted stock units and stock options granted on March 18, 2024.

Summary

• Noah Berkowitz, Chief Medical Officer of Arvinas Inc., filed a Form 4 detailing changes in beneficial ownership.
• On March 18, 2024, Berkowitz was granted 63,452 restricted stock units (RSUs) and an option to purchase 93,879 shares of common stock at an exercise price of $42.60.
• The RSUs and options were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and not pursuant to the company's 2018 Stock Incentive Plan.
• The RSUs vest over four years, with 25% vesting annually on March 18, from 2025 to 2028, contingent upon continued service.
• The options also vest over four years, with 1/4 vesting on March 18, 2025, and the remainder vesting in equal monthly installments until March 18, 2028.
• Following these transactions, Berkowitz beneficially owns 63,452 shares of Arvinas Inc. common stock and options for 93,879 shares.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The document reports standard executive compensation practices, which are generally viewed favorably as they align management interests with shareholders.

Positives

• The grant of RSUs and stock options to the Chief Medical Officer aligns his interests with those of the shareholders.
• The vesting schedule incentivizes continued service and commitment to the company's long-term success.

Industry Context

Stock option and RSU grants are a common practice in the biotechnology industry to attract and retain key executives. These grants align executive compensation with company performance and shareholder value.

Comparison to Industry Standards

• Companies like Amgen, Gilead, and Biogen also use stock options and RSUs as part of their executive compensation packages.
• The vesting schedules are fairly standard, typically ranging from three to five years, to incentivize long-term commitment.
• The specific amounts and terms of the grants would need to be compared to peer companies to determine if they are in line with industry norms.

Stakeholder Impact

• Shareholders may view the grants positively as they incentivize management to improve company performance.
• Employees may see the grants as a sign of the company's commitment to its leadership.

Key Dates